From a ScienceDaily.com online release:
Physical inactivity, smoking, high blood pressure, diabetes, and high cholesterol play a greater role than genetics in many young patients with heart disease, according to research presented today at ESC Congress 2019 together with the World Congress of Cardiology. The findings show that healthy behaviours should be a top priority for reducing heart disease even in those with a family history of early onset.
The study enrolled 1,075 patients under 50, of whom 555 had coronary artery disease (known as premature CAD). Specific conditions included stable angina, heart attack, and unstable angina. The average age was 45 and 87% were men. Risk factor levels and genetics in patients were compared to a control group of 520 healthy volunteers (average age 44, and 86% men). Patients and controls were recruited from the Genes in Madeira and Coronary Disease (GENEMACOR) database.
Five modifiable risk factors were assessed: physical inactivity, smoking, high blood pressure, diabetes, and high cholesterol. Nearly three-quarters (73%) of patients had at least three of these risk factors compared to 31% of controls. In both groups, the likelihood of developing CAD increased exponentially with each additional risk factor. The probability of CAD was 3, 7, and 24 times higher with 1, 2, and 3 or more risk factors, respectively.
To read more: https://www.sciencedaily.com/releases/2019/09/190902181602.htm
Our results further suggest that optimism is specifically related to 11 to 15% longer life span, on average, and to greater odds of achieving “exceptional longevity,” that is, living to the age of 85 or beyond. These relations were independent of socioeconomic status, health conditions, depression, social integration, and health behaviors (e.g., smoking, diet, and alcohol use). Overall, findings suggest optimism may be an important psychosocial resource for extending life span in older adults.
He wondered whether lithium could have the same tranquillizing effect on his patients. After trying it out on himself to establish a safe dose, Cade began treating ten people with mania. In September 1949, he reported fast and dramatic improvements in all of them in the Medical Journal of Australia (
Health care is a big business, and our system reimburses hospitals and health care workers for caring for the sickest people rather than healthiest ones. This process depletes healers’ energy and often causes them to become exhausted and sick. That means all of us who work in or study to work in health care are at risk. To break this vicious cycle, we need self-scrutiny and willingness to change.
“What is memory without forgetting?” asks Oliver Hardt, a cognitive psychologist studying the neurobiology of memory at McGill University in Montreal, Canada. “It’s impossible,” he says. “To have proper memory function, you have to have forgetting.”
“While we always believed that high levels of uric acid might be bad for kidneys and that patients with gout may have a higher risk of kidney failure, we were quite surprised by the magnitude of the risk imposed by gout in these patients. We were particularly interested in the risk of advanced kidney disease, as these patients in general have a higher risk of kidney failure and death.
Now, researchers have developed a fast-acting skin patch that efficiently delivers medication to attack melanoma cells. The device, tested in mice and human skin samples, is an advance toward developing a vaccine to treat melanoma and has widespread applications for other vaccines.
In sarcoidosis, abnormal collections of cells called granulomas invade the organ, interfering with its normal activity and often destroying the surrounding tissue. What is left is a scar, known as fibrosis, dotted with these abnormal granulomas.
Use of polypill was effective in preventing major cardiovascular events. Medication adherence was high and adverse event numbers were low. The polypill strategy could be considered as an additional effective component in controlling cardiovascular diseases, especially in LMICs.
The use of n-3 FA (4 g/d) for improving atherosclerotic cardiovascular disease risk in patients with hypertriglyceridemia is supported by a 25% reduction in major adverse cardiovascular events in REDUCE-IT (Reduction of Cardiovascular Events With EPA Intervention Trial), a randomized placebo-controlled trial of EPA-only in high-risk patients treated with a statin.
